Mesenchymal stem cells (MSCs) are a potential source of chondrogenic cells for the treatment of cartilage disorders, but loss of chondrogenic potential during in vitro expansion and the propensity of cartilage to undergo hypertrophic maturation impede their therapeutic application. Here we report that the signaling protein WNT3A, in combination with FGF2, supports long-term expansion of human bone marrow-derived MSCs. The cells retained their chondrogenic potential and other phenotypic and functional properties of multipotent MSCs, which were gradually lost in the absence of WNT3A. Moreover, we discovered that endogenous WNT signals are the main drivers of the hypertrophic maturation that follows chondrogenic differentiation. Inhibition of WNT signals during differentiation prevented calcification and maintained cartilage properties following implantation in a mouse model. By maintaining potency during expansion and preventing hypertrophic maturation following differentiation, the modulation of WNT signaling removes two major obstacles that impede the clinical application of MSCs in cartilage repair.
INTRODUCTION
Cartilage is an avascular, alymphatic, and aneural tissue (Mankin, 1982) that, consequently, has limited repair capacity. Therefore, cartilage damage requires clinical intervention. In the last two decades, cell-based therapies have emerged as promising treatment options. Autologous chondrocyte implantation (ACI) was first applied in 1994 and is still used to treat cartilage defects in human patients (Brittberg et al., 1994) . In ACI, however, chondrocytes are harvested from the patient, creating an additional cartilage defect. Moreover, before use, the chondrocytes require in vitro expansion, which causes the progressive loss of cartilage matrix gene expression (Benya et al., 1978; Mayne et al., 1976) .
Mesenchymal stem cells (MSCs) from adult tissues, with their ability to differentiate into several cell types, chondrocytes included, have been investigated as an alternative cell source (Dennis et al., 1999; Pittenger et al., 1999; Prockop, 1997) . Unfortunately, despite their easy isolation and in vitro expansion, the loss of stem cell characteristics and differentiation potential with expansion (Banfi et al., 2000; Bonab et al., 2006; Chen et al., 2005; Li et al., 2011) and the induction of hypertrophic maturation following chondrogenic differentiation (Hellingman et al., 2010; Pelttari et al., 2006; Scotti et al., 2010) limit their appeal. Expansion of MSCs is improved in the presence of fibroblast growth factor 2 (FGF2) (Bianchi et al., 2003; Quarto et al., 2001; Solchaga et al., 2005; Tsutsumi et al., 2001 ), but FGF2 does not prevent the gradual loss of cell multipotency or the subsequent formation of hypertrophic cartilage (Farrell et al., 2009; Hellingman et al., 2010; Pelttari et al., 2006) . A major challenge therefore is to identify the factors that support MSC expansion while maintaining their chondrogenic capacity, and additionally the factors that regulate hypertrophic maturation.
To identify such factors, we took inspiration from the process of cartilage and bone formation during embryonic development. In developing mouse limbs, skeletal tissues are generated by a rapidly expanding population of multipotent mesenchymal cells, found at the tip of the embryonic limb bud (Rabinowitz and Vokes, 2012; Zeller et al., 2009) . The expansion of these multipotent cells is driven by the combination of WNT and FGF signals, secreted by the apical ectodermal ridge (ten Berge et al., 2008a) . The combination of WNT and FGF proteins synergistically supports the expansion of these cells in vitro while maintaining their multilineage potential (Cooper et al., 2011; ten Berge et al., 2008a) . Furthermore, WNT signals also play an important role during cell differentiation, where their ability to modulate chondrogenesis and induce osteogenesis is well established both in vitro (Churchman et al., 2012; Dong et al., 2007; Jullien et al., 2012) and in vivo (Day et al., 2005; Quarto et al., 2010a Quarto et al., , 2010b .
In this paper, we show that the combination of WNT3A and FGF2 supports extensive expansion of adult human bone marrow-derived MSCs over multiple passages while maintaining robust chondrogenic potential. Furthermore, we show that inhibition of WNT signals during chondrogenic differentiation prevents undesired hypertrophic maturation, allowing the formation of stable cartilage in vivo.
RESULTS

WNT3A and FGF2 Synergistically Promote MSC Proliferation and Chondrogenic Potential
MSCs were isolated from adult human bone marrow aspirates by selective plastic adherence ( Figure 1A ), followed by phenotypic characterization using flow cytometry.
This confirmed the cells were positive (>95%) for the MSC markers CD73, CD90, and CD105 and negative (<0.5%) for the hematopoietic marker CD45 ( Figure S1A ). Afterward, we verified that MSCs responded to WNT3A protein by demonstrating the accumulation of nonphosphorylated b-CATENIN ( Figure S1B ) and induction of the WNT target gene AXIN2 ( Figure S1C ). Treatment with FGF2 did not influence nonphosphorylated b-CATENIN accumulation ( Figure S1B ).
We next analyzed the effects of WNT3A and FGF2 on cell proliferation. We observed that treatment of MSCs with either WNT3A or FGF2 enhanced cell proliferation to a similar degree ( Figure 1B) . Moreover, proliferation was further increased by combining WNT3A with FGF2, showing a synergistic effect of the two factors ( Figure 1B ; fold increase in cell number compared to +vehicle: +WNT = 1.53; +FGF = 1.29; +WNT+FGF = 4.81). The synergistic action of WNT3A and FGF2 maintained a constant exponential expansion even after six passages, leading to Values represent means ± SEM of three donors. *p < 0.05, **p < 0.01, ***p < 0.001, # p < 0.01 compared to the other conditions.
an approximately 10 9 -fold expansion, whereas in the presence of FGF alone expansion slowed down over time and came practically to a halt after 30 days ( Figure 1C ). Upon differentiation in pellet culture, although the chondrogenic differentiation of MSCs was performed using the same chondrogenic medium composition, MSCs expanded in the presence of both WNT3A and FGF2 (WF-MSCs) displayed an increased chondrogenic capacity compared to cells expanded in the presence of FGF2 alone (F-MSCs) ( Figures 1D and 1E) . Interestingly, WF-MSCs formed larger pellets ( Figure 1F ) that contained higher levels of the cartilage matrix components collagen type II and glycosaminoglycans ( Figures 1D and 1E) . Nonetheless, total cell numbers in the pellets were comparable throughout the chondrogenic induction and between the conditions, indicating that WF-MSCs produced more cartilage matrix per cell upon differentiation compared to F-MSCs ( Figure S2 ). Cells expanded in the absence of FGF2, regardless of the presence of WNT3A, displayed a limited chondrogenic differentiation capacity ( Figure 1D ). Together, these data indicate that WNT and FGF synergize to not only increase proliferation but also enhance the chondrogenic potential of MSCs after short-term expansion.
We next asked whether WF-MSCs could maintain their chondrogenic potential when expanded over multiple passages. We passaged the cells every 5 days and assessed their chondrogenic potential by pellet culture at every passage ( Figure 2A ). Although WF-MSCs expanded faster (Figure 2B) , they maintained robust chondrogenic potential over the course of four passages ( Figure 2C ), whereas F-MSCs gradually lost their ability to produce an extracellular matrix rich in glycosaminoglycans ( Figure 2D ). Cell-count analysis showed that pellets derived from WFMSCs contained more extracellular matrix and lower cell density than pellets from F-MSCs ( Figures 2C and 2D , right panels). These observations demonstrate that both WNT and FGF signals are required for the long-term expansion of MSCs with high chondrogenic potential.
An additional benefit of the presence of WNT3A and FGF2 during MSC expansion appeared when we observed the faster differentiation of WF-MSCs compared to F-MSCs: 3 weeks after chondrogenic induction, expression levels of collagen type II (COL2) and collagen type IIB (COL2B; a splice variant of collagen type II expressed during late chondrogenesis; McAlinden et al., 2008) were twice as high in WF-MSCs as in F-MSCs ( Figure 3A) . After 5 weeks, at the end of the differentiation protocol, transcript levels were not significantly different from each other ( Figure 3B ; +FGF versus +WNT+FGF), indicating that the increased collagen type II protein accumulation we observed ( Figure 1D ) was the result of increased deposition earlier during differentiation. In agreement with this, we observed that glycosaminoglycans accumulated faster in pellets formed with WF-MSCs than in F-MSC pellets ( Figure 3C ).
Although MSCs can express several WNT ligands (Cho et al., 2006; Etheridge et al., 2004) , endogenous WNT signaling appears to play a negligible role in MSC expansion, because we found no effects on cell proliferation or subsequent differentiation when endogenous WNT proteins were blocked by the WNT antagonist Fz8CRD or when endogenous WNT production was inhibited by the porcupine inhibitor IWP2 ( Figure S3 ).
Together, these results demonstrate that WNT3A, in cooperation with FGF2, not only enhances long-term MSC chondrogenic potential but also accelerates their subsequent chondrogenic differentiation.
In Vitro WNT Signaling Modulation Leads to Stable Cartilage Formation In Vivo A major obstacle preventing the use of MSCs for cartilage repair is their tendency to initiate endochondral ossification following chondrogenic differentiation. This can be observed as accumulation of collagen type X (COL10), matrix metalloproteinase 13 (MMP13; also known as collagenase 3), and alkaline phosphatase (ALP) during hypertrophic maturation (Hellingman et al., 2010 (Hellingman et al., , 2011 , followed by calcification of the tissue and blood vessel invasion, steps that ultimately lead to bone formation (Farrell et al., 2011; Scotti et al., 2010) . Encouragingly, although WFMSCs demonstrated an enhanced chondrogenic potential, they did not display an increase in collagen type X protein accumulation during chondrogenic differentiation ( Figure 4A ). Although COL10 expression was upregulated after 3 weeks in pellet culture, in line with the faster COL2 production, it did not further increase during the last 2 weeks of differentiation ( Figure 4B ). In contrast, F-MSCs continued to increase COL10, ultimately resulting in higher expression after 5 weeks of differentiation ( Figure 4B ). Moreover, WF-MSCs also expressed lower levels of MMP13 at both time points ( Figure 4C ). This suggests that WF-MSCs may have a lower propensity to undergo hypertrophic maturation during chondrogenic induction.
We further investigated the stability of the cartilage by implanting the differentiated pellets subcutaneously in immunocompromised (NMRI nu/nu) mice for 8 weeks ( Figure 4D ), a well-established model for testing cartilage stability in vivo (De Bari et al., 2004; Pelttari et al., 2006) . We found that F-MSC-derived pellets displayed weak collagen type II staining, large areas of calcification, and blood vessel invasion ( Figure 4E , left panels), indicating the onset of endochondral ossification. In contrast, WF-MSC-derived pellets were strongly positive for collagen type II and displayed no blood vessel invasion after implantation ( Figure 4E , right panels). However, calcified cartilage was observed, indicating that WF-MSCs ultimately underwent endochondral ossification in vivo, although the process may be delayed ( Figure 4E ).
Multiple reports indicate that WNT signals promote osteogenic differentiation of multipotent progenitors during endochondral ossification (Cawthorn et al., 2012; Day and Yang, 2008) . Indeed, the WNT target AXIN2 was expressed in MSCs during chondrogenic differentiation and repressed by IWP2, indicating it was due to endogenous WNT signals ( Figure 4F ). We therefore tested whether inhibition of WNT signals during chondrogenic induction would prevent hypertrophic maturation. When chondrogenic differentiation was performed in the presence of IWP2, both F-MSCs and WF-MSCs showed reduced AXIN2 expression ( Figure 4F ). Although only small changes in COL10 and MMP13 mRNA levels were observed, ALP was strongly downregulated by IWP2 ( Figure 4F ). Interestingly, WF-MSC-derived pellets displayed the lowest levels of AXIN2, COL10, MMP13, and ALP and the highest levels of glycosaminoglycan deposition and COL2, resulting in the greater COL2:COL10 ratio, particularly in the presence of IWP2 (Figures 4F and 4G, upper panels; Figure S4) . Importantly, upon implantation in NMRI nu/nu mice, the IWP2-treated pellets derived from WF-MSCs displayed strong collagen type II staining, with no signs of calcification or blood vessel invasion ( Figure 4G ). Altogether, these results show that inhibition of endogenous WNT production interferes with hypertrophic maturation and supports the formation of cartilage from WF-MSCs that remains stable in our in vivo model.
WNT3A and FGF2 Maintain MSC Phenotype, Gene Expression, and Multipotency over Multiple Passages
Because MSCs from bone marrow constitute a heterogeneous population of cells Pittenger et al., 1999) , our findings suggest that, in the absence of WNT signals, the chondrogenic progenitors are gradually depleted during expansion. In order to evaluate this hypothesis, we characterized the cells prior to chondrogenic differentiation. Whereas WF-MSCs maintained a polygonal-like phenotype during expansion, F-MSCs gradually acquired a more heterogeneous and enlarged morphology ( Figure 5A ; Figure S5A ). We further characterized the phenotypic composition of the expanding population using flow cytometry for the MSC markers CD90, CD105, CD73, CD166, CD271, and CD146 (Dominici et al., 2006; Hermida-Gómez et al., 2011; Sacchetti et al., 2007) . At passage 1, >90% of the cells expressed the MSC markers CD90, CD105, CD73, and CD166 regardless of the presence of WNT3A (Figure 5B) . Moreover, WF-MSCs displayed a higher expression of CD271, a protein associated with the chondrogenic subset of MSCs ( Figure 5B ) (Hermida-Gó mez et al., 2011). CD146, which in bone marrow may be a marker of osteoprogenitor (Sacchetti et al., 2007) , was lost from the cells independent of treatment with WNT3A ( Figure S5B) .
Following expansion over four passages, F-MSCs had decreased expression of CD90 and CD105, whereas this expression was maintained in the presence of WNT3A (Figure 5B) . Furthermore, CD73 decreased in the absence of WNT3A, whereas CD166 decreased in both conditions but less in the presence of WNT3A ( Figure 5B ). Combined, these data suggest that WNT3A in combination with FGF2 preferentially allowed the expansion of MSCs characterized by polygonal morphology, small cell size, and high expression of CD90, CD105, CD73, CD166, and CD271. Moreover, we investigated whether multipotency of the cells was maintained ( Figure 5C ), and found that WNT3A in combination with FGF2 retained the adipogenic and osteogenic potential of the cells, even after four passages ( Figures 5D and 5E ).
Finally, we investigated how WNT and FGF affect the expression of genes involved in proliferation and cell-fate commitment. MYC genes mediate the proliferative effect of WNT in mouse chondrogenic progenitors (ten Berge et al., 2008a) . Interestingly, WNT3A and FGF together maintained high levels of MYC and NMYC, although their expression declined in the absence of WNT3A ( Figure 5F ). The third MYC family member, MYCL1, was not detected (data not shown). TWIST1 is associated with the uncommitted and proliferative state of MSCs (Isenmann et al., 2009 ) by stimulating ID1 and influencing cell differentiation via the regulation of lineage-specific transcription factors (Menicanin et al., 2010; Yang et al., 2011) . Again, WNT3A together with FGF2 maintained high levels of (legend continued on next page) TWIST1, ID1, and the chondrogenic master regulator SOX9, whereas the levels of these markers declined with the expansion in the absence of WNT3A ( Figure 5F ). Interestingly, TWIST1, ID1, and SOX9 were not responsive to either WNT3A or FGF2 but only responded to simultaneous stimulation of these factors ( Figure S5C ), suggesting a possible mechanism for their synergistic effect. Combined, these data suggest that the combination of WNT3A and FGF2 maintains the uncommitted and proliferative state of MSCs by supporting the expression of TWIST1 and MYC genes while maintaining their chondrogenic potential by supporting SOX9 expression.
DISCUSSION
MSCs from adult tissues are currently used in cartilage tissue engineering but gradually lose their stem cell characteristics during in vitro expansion, leading to a decreased chondrogenic differentiation capacity (Banfi et al., 2000; Bonab et al., 2006; Chen et al., 2005; Li et al., 2011) . Moreover, the cartilage undergoes hypertrophic maturation (Farrell et al., 2011; Hellingman et al., 2011) . In this study, we demonstrate that MSCs from adult human bone marrow depend on WNT signals to maintain their chondrogenic potential during expansion. Furthermore, by inhibiting WNT signaling during the subsequent chondrogenic differentiation phase, we not only enhanced chondrogenesis further but also prevented the onset of endochondral ossification in our in vivo model ( Figure 6 ). Several additional benefits arose from the use of WNT3A protein during expansion of MSCs: the cells proliferated faster, their subsequent chondrogenic differentiation took less time, and expression of hypertrophic markers was reduced. These findings have the potential to remove several major obstacles to clinical application of MSCs in the repair of large cartilage defects, reducing the time of culture while increasing the quality of the engineered cartilage and preventing calcification.
The positive effect of FGF2 on enhancing proliferation and chondrogenic potential of MSCs is well established (Handorf and Li, 2011; Mastrogiacomo et al., 2001; Solchaga et al., 2005; Tsutsumi et al., 2001 ). Whereas we find that FGF2 sustains cell proliferation for up to $20 cell doublings, some reports show that it sustains cell proliferation up to 40-50 cell doublings (Auletta et al., 2011; Banfi et al., 2000; Gharibi and Hughes, 2012; Solchaga et al., 2010) . However, in these studies, healthy and young donors (an average of 30 years old) were used, whereas we investigated cells from elderly patients, who are more likely to require cartilage repair. In addition, these studies report an average of 22 doublings in 40 days, whereas we find that WNT3A and FGF2 support 30 cell doublings in this time frame, despite the increased age of the donors. Thus, WNT3A not only sustains prolonged FGF2-promoted cell expansion but also enhances the proliferation rate.
MSCs can express several WNT ligands (Cho et al., 2006; Etheridge et al., 2004) . This endogenous WNT signaling may play a negligible role in MSC expansion, because we found no significant effects on cell proliferation or subsequent differentiation when endogenous WNT proteins were prevented. However, and in agreement with our findings, it has been reported that inhibition of endogenous WNT signaling specifically during MSC differentiation increased their chondrogenic differentiation (Im et al., 2011; Im and Quan, 2010 ). Furthermore, a decreased level of b-CATENIN in differentiating MSCs was previously associated with the downregulation of the hypertrophic marker COL10 (Venkatesan et al., 2012) , consistent with our finding that WNT repression suppressed the induction of hypertrophic markers.
We show that adult human MSCs expanded with WNT3A and FGF2 retained some of their surface markers after extensive expansion in vitro. WNT3A and FGF2 may specifically support the expansion of a chondrogenic or multipotent subset of MSCs, preventing the gradual accumulation of cells that do not contribute to chondrogenesis. 
(legend continued on next page)
Evidence for this is the loss of SOX9 expression and the accumulation of CD90-, CD105-, CD166-, and CD271-negative populations in the absence of WNT3A. Selective maintenance of a chondrogenic subpopulation may also explain the accelerated chondrogenesis that WF-MSCs undergo. CD146 was identified as a marker for bone marrow-derived MSCs with osteoprogenitor capacity in vivo (Sacchetti et al., 2007) . Upon expansion with FGF2, with or without WNT3A, we find no CD146 expression; however, the cells retain proliferation and multilineage differentiation potential, in particular in the presence of WNT3A. Thus, although CD146 may be an in vivo marker for MSCs, it does not mark multipotent MSCs after in vitro expansion.
Genes associated with the WNT pathway have been indicated as potential candidates to maintain MSCs in an uncommitted state and to enhance their proliferation capacity (Boland et al., 2004; Cho et al., 2006) . We have previously shown that WNT and FGF signals interact during embryonic cartilage development to stimulate mesenchymal cell proliferation while maintaining their multipotency (ten Berge et al., 2008a) . In that system, WNT and FGF synergize in promoting cell proliferation by inducing NMYC, which mediates cell-cycle entry in response to proliferative signals while simultaneously preventing chondrogenic differentiation by repressing the essential chondrogenic regulator SOX9 (ten Berge et al., 2008a) . This difference may arise from the different experimental contexts: whereas our human MSCs were in an undifferentiated, expanding state, the mouse cells had started to differentiate along the chondrogenic lineage, thereby strongly upregulating SOX9. Whereas in the mouse system, WNT prevents the upregulation of SOX9, in expanding human MSCs the maintenance of SOX9 may indicate the preservation of chondrogenic potential. Consistent with this, the induction of SOX9 goes in parallel with a synergistic effect of WNT3A and FGF2 on TWIST1 expression, a marker commonly associated with an uncommitted state (Isenmann et al., 2009; Menicanin et al., 2010) .
Our findings underline the importance of stage-dependent modulation of WNT signals in leading MSCs toward a stable cartilage fate, and also indicate how insights obtained from developmental biology contribute to generating new strategies for regenerative medicine. Prior to clinical translation, more prolonged in vivo experiments in larger animals may be needed to validate the benefit of WNT signaling modulation. Moreover, alternative delivery methods for the cells, for example cell suspensions in injectable hydrogels, may increase the applicability for tissue-engineering approaches.
EXPERIMENTAL PROCEDURES
Purified WNT3A and WNT Inhibitors WNT3A was purified from cell-culture medium conditioned by Drosophila S2 cells modified with a mouse WNT3A expression vector as described (Willert et al., 2003) . The purified protein was obtained as a solution of 50 mg ml À1 in PBS + 1% 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS). The competitor of the WNT receptor Frizzled, Fz8CRD, was produced as a fusion protein (Fz8CRD-IgG) as previously described (Hsieh et al., 1999) . The WNT-secretion inhibitor N-(6-methyl-2-benzothiazolyl)-2-[(3,4,6,7-tetrahydro-4-oxo-3-phenylthieno[3,2-d]pyrimidin-2-yl)thio]-acetamide (IWP2) was purchased from Stemgent and dissolved in DMSO, obtaining a stock solution of 2 mM. IWP2 specifically inhibits the maturation (endogenous production) of WNT proteins by blocking the acyltransferase enzyme porcupine. 50,000 nucleated cells cm À2 in alpha-MEM (GIBCO), supplemented with 10% fetal calf serum (FCS), 1 ng ml À1 FGF2 (AbD Serotec), 25 mg ml À1 ascorbic acid-2-phosphate (Sigma-Aldrich), 1.5 mg ml À1 fungizone, and 50 mg ml À1 gentamicin. MSCs were isolated by their ability to adhere to plastic culture flasks. After 24 hr, nonadherent cells were washed out and adherent cells were cultured in standard conditions (5% CO 2 at 37 C) for 10 ± 2 (mean ± SD, n = 6 donors) days. Medium was renewed three times per week. When MSCs neared confluence, they were detached with 0.05% trypsin and characterized by flow cytometry. Cells were resuspended at 750,000 cells ml À1 in FACSFlow solution (BD Biosciences).
Cell Source and Isolation of MSCs from Bone Marrow
Expansion Phase
After isolation, MSCs were trypsinized using 0.05% trypsin and reseeded at a density of 2,300 cells cm À2 in alpha-MEM + 10% FCS + 25 mg ml À1 ascorbic acid-2-phosphate supplemented as follows:
(1) no supplementation (+vehicle) (2) + 250 ng ml À1 WNT3A (+WNT) (3) + 1 ng ml À1 FGF2 (+FGF) (4) + 250 ng ml À1 WNT3A + 1 ng ml À1 FGF2 (+WNT+FGF) (5) + 250 ng ml À1 WNT3A + 1 ng ml À1 FGF2 + 2 mM IWP2
(+WNT+FGF+IW) (6) + 1 ng ml À1 FGF2 + 2 mM IWP2 (+FGF+IW) (7) + 1 ng ml À1 FGF2 + 2 mg ml À1 Fz8CRD (+FGF+FZ).
The concentrations of WNT3A and FGF2 used were based on previous reports (Martin et al., 1997; ten Berge et al., 2008b ten Berge et al., , 2011 . Vehicle consisted of PBS + 1% CHAPS and/or DMSO, as applicable. Medium was renewed every 24 hr. After one passage (P1), cells were harvested, counted, and used to assay the chondrogenic potential by pellet culture. Alternatively, MSCs were expanded up to P4 using an expansion condition in the presence of FGF2 or WNT3A and FGF2. With every passage in a monolayer, cells were harvested, counted, and then transferred to a pellet-culture system to assess the chondrogenic potential or replaced for the next expansion. Cell doublings were determined using the following formula: doublings = log 2 (cells at the end of the passage/cells seeded).
FACS Analysis
Cells were resuspended at 750,000 cells ml À1 in FACSFlow solution (BD Biosciences) and stained with antibodies against human CD45-PerCp (345809), CD73-PE (550257), CD140a-PE (556002), CD146-FITC (560846), CD166-PE (559263), CD271-Alexa Fluor (560326) (BD Biosciences), CD90-APC (FAB2067A), and CD105-FITC (FAB10971F) (R&D Systems), following the manufacturer's guidelines. Unstained samples were used as negative controls. Flow cytometry analysis was performed using the BD FACSCanto II apparatus (BD Biosciences), and data were analyzed using BD FACSDiva software (BD Biosciences).
Chondrogenic Differentiation
After expansion, MSCs were harvested and centrifuged at 200 3 g for 8 min to obtain pellets of 200,000 cells. Chondrogenic differentiation was induced by culturing the cells for 5 weeks in chondrogenic medium consisting of DMEM-high-glucose GlutaMAX+ (GIBCO), 1:100 insulin, transferrin, and selenous acid (ITS+; BD Biosciences), 40 mg ml À1 L-proline (Sigma-Aldrich), 1 mM sodium pyruvate (GIBCO), 100 nM dexamethasone (Sigma-Aldrich), 10 ng ml À1 transforming growth factor b1 (TGF-b1; R&D Systems), 1.5 mg ml À1 fungizone, and 50 mg ml À1 gentamicin. Medium was renewed twice a week. Alternatively, the WNT inhibitor IWP2 (2 mM) was added during the last 3 weeks of chondrogenic induction. For this experiment, medium was renewed three times per week.
Gene Expression Analysis
Cells in monolayers were washed with PBS and treated on ice with RLT lysis buffer (QIAGEN). After 3, 4, or 5 weeks in chondrogenic induction medium, pellets were manually homogenized in RNABee (Tel-Test) and RNA was extracted by addition of 20% chloroform. In all cases, RNA was purified using an RNeasy Micro kit (QIAGEN) and 1 mg of total RNA was reverse transcribed into cDNA using a RevertAid First Strand cDNA synthesis kit (MBI Fermentas). Polymerase chain reactions were performed with TaqMan Universal PCR MasterMix (Applied Biosystems) or SYBR Green MasterMix (Fermentas) using an ABI PRISM 7000 apparatus. Primers and probe sets (Table S1 ) were designed using Primer Express 2.0 software (Applied Biosystems). Data were normalized to GAPDH after its identification as the more stable within the conditions and over time. Relative expression was calculated according to the 2 ÀDDCt formula (Schmittgen and Livak, 2008) .
Cartilage Stability In Vivo
Pellets from P2-expanded cells were implanted subcutaneously in 10-to 14-week-old female NMRI nu/nu mice (Charles River Laboratories). The mice were anesthetized using a mixture of isoflurane/ O 2 and four pellets per donor and condition were implanted by a blinded technician in two separate subcutaneous pockets. After 8 weeks, the animals were sacrificed and the samples were harvested, fixed in 4% formalin, and subjected to a microcomputed tomography (mCT) scan. Afterward, samples were decalcified with 10% EDTA in PBS (pH 7.4) for 5 days and then paraffin embedded, sectioned, and used for (immuno)histochemistry. Animal experiments were carried out in the central animal facilities at Erasmus MC with approval of the Animal Experiments Committee according to the national animals act (EMC 2429).
(Immuno)Histochemistry In Vitro Samples
Pellets were fixed in 4% formalin and paraffin embedded. Four sections (6 mm) of each sample were stained with 0.4% thionine solution (Sigma-Aldrich) in demineralized water to detect glycosaminoglycans or immunostained to detect collagen type II or collagen type X as previously described (Hellingman et al., 2010) . Briefly, antigen retrieval was performed with 0.1% pronase (Sigma-Aldrich) in PBS for collagen type II and with 0.1% pepsin (Sigma-Aldrich) in 0.5 M acetic acid (pH 2.0) for collagen type X staining. Both stainings continued with incubation with 10 mg ml À1 hyaluronidase (Sigma-Aldrich) in PBS. Then, sections were incubated for 2 hr with primary antibody for collagen type II (II-II/II6B3; Developmental Studies Hybridoma Bank, University of Iowa) or 16 hr with collagen type X (2031501005; Quartett). Alkaline phosphatase-labeled secondary antibody was used in combination with Neu Fuchsine substrate, resulting in a red staining. An isotype IgG1 monoclonal antibody was used as a negative control. NIH ImageJ freeware was used to evaluate the size of the pellets on sections taken from the middle of the pellet and the percentage of the thionine-positive areas and to quantify the number of cells per mm 2 in the sections stained by thionine.
In Vivo Samples
After 8 weeks in vivo, pellets were decalcified as described above, paraffin embedded, sectioned, and either immunostained for collagen type II or stained with hematoxylin (Sigma-Aldrich) for 5 min followed by counterstaining with 2% eosin solution (Merck) in 50% ethanol. Collagen type II immunostaining was performed as described for the in vitro samples but using the primary antibody previously incubated overnight with a goat anti-mouse biotin-conjugated antibody (115-066-062; Jackson ImmunoResearch Europe). An isotype IgG1 monoclonal antibody was used as a negative control. All the (immuno)histological evaluations were performed in collaboration with an experimentally blinded technician.
DNA and Glycosaminoglycan Quantification
Pellets at days 3, 7, 10, 14, 17, 21, 24, 28, 31 , and 35 of culture were digested with 300 ml of proteinase K solution (1 mg ml À1 proteinase K, 50 mM Trizma base, 1 mM EDTA, 1 mM iodoacetamide, 10 mg ml À1 pepstatin [pH 7.6]; all from Sigma-Aldrich) for 16 hr at 60 C. After digestion, proteinase K was inactivated for 10 min at 105 C.
DNA Quantification
Five to 20 ml of each proteinase K-digested sample was loaded in technical triplicate on an ice-cold 96-well plate. After incubation with heparin (8.3 U ml À1 in PBS; Leo Pharma) and RNase solution (0.05 mg ml À1 in PBS; Sigma-Aldrich), 50 ml of ethidium bromide (25 mg ml À1 in PBS; GIBCO) was added to each sample. Using the Wallac 1420 VICTOR 2 (PerkinElmer) apparatus, the ratio between the absorbance at 340 nm (extinction filter) and the absorbance at 590 nm (emission filter), corrected by the background (wells loaded with PBS only), was calculated. Purified calf thymus DNA (Sigma-Aldrich) was used to set the standard curve.
Glycosaminoglycan Assay 1,9-dimethylmethylene blue (DMB; Sigma-Aldrich) solution (46 mM DMB, 40 mM glycine, 40 mM NaCl [pH 3.0]) was added to proteinase K-digested samples (200 ml) and the 530:590 nm absorbance ratio was measured to determine the glycosaminoglycan amount, using chondroitin sulfate C (Sigma-Aldrich) as a standard.
MicroCT Analysis
After in vivo implantation, pellets from two MSC donors (n = 2 donors, four pellets per donor and condition) were analyzed by the Quantum FX mCT scanner (PerkinElmer) using the following settings: isotropic voxel size of 10 mm, 70 kV, 160 mA, 5 mm field of view, 3 min scan (FINE setting) per sample. Raw mCT images were converted into 3D reconstructions using Quantum FX mCT software (PerkinElmer).
Statistical Analysis
Data were analyzed with PASW Statistics 20 (SPSS). The normal distribution of data was confirmed using the Kolmogorov-Smirnov 
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Western blot. After P1-expansion, and 3 h after last medium renew, MSC of two donors were harvested using M-PER Protein extraction reagent (Thermo Scientific, Rockford, IL, USA) with 1% protease inhibitor (Roche, Mannheim, Germany). Equal amounts of protein lysate were subjected to 10% SDS-PAGE gels and transferred on PVDF membranes.
Membranes were blocked (0.1% tris/tween buffer containing 5% dry milk powder) and then incubated overnight at 4°C with primary antibody (Table S2) . Afterwards, anti-rabbit secondary antibody was added for 1 h at room temperature. Antibodies were purchased from Cell Signaling Technology (Leiden, the Netherlands). The blots were visualized with SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific, Rockford, IL, USA) following manufacturer's instructions.
Osteogenic differentiation. Cells were seeded at 3,000 cells cm -2 and cultured for 18 days with DMEM-high glucose (Gibco) + 10% FCS, 50 μg ml -1 gentamicin, 1.5 μg ml -1 fungizone, β-glycerophosphate 10 mM, dexamethasone 0.1 μM and L-ascorbic acid 2 phosphate 0.5 mM (all from Sigma-Aldrich). Cultures were fixed in 10% formalin, hydrated with water and treated with 5% silver nitrate solution (Sigma-Aldrich) for 10 minutes. Excess staining was removed with 5% sodium-thiosulphate (Sigma-Aldrich) followed by counterstaining with azophloxine (Sigma-Aldrich).
Adipogenic differentiation. Cells were seeded at 20,000 cells cm -2 and cultured for 3 weeks in DMEM-high glucose (Gibco) + 10% FCS, supplemented with 50 μg ml -1 gentamicin, 1.5 μg ml -1 fungizone, dexamethasone 1 μM, indo-methacin 0.2 mM, insulin 0.01 mg ml -1 , and 3-isobutyl-l-methyl-xanthine 0.5 mM (all from Sigma-Aldrich). Cultures were fixed in 10% formalin, treated with 0.3% Oil red O solution (Sigma-Aldrich) for 15 min, and then washed with tap water. Table S1 -SYBR/Taqman primer and probe sequences All antibodies used for western Blot were purchased from Cell Signalling
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